Pharmacoepidemiological characteristics of antibacterial drug prescriptions used in patients with exacerbation of chronic pyelonephritis in real-life practice in Kursk and Chisinau

Povetkin S.V., Kornilov A.A., Levashova O.V., Zhilyaeva Yu.A., Bachinsky N.G., Podgursky L.A., Tsurkan L.M., Golovach I.N.

1) Kursk State Medical University, Department of Clinical Pharmacology, Kursk, Russia; 2) Kursk State Medical University, Department of Internal Medicine No. 2, Kursk, Russia; 3) Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Background. Urinary tract infections (UTIs) are among the most common diseases. One of the promising ways to optimize antibacterial therapy for UTIs is to conduct pharmacoepidemiological studies.
Objective. Evaluation of the structure of medical prescriptions for antibacterial drugs used in patients with exacerbation of chronic pyelonephritis (PN) in real-life practice in Kursk (Russian Federation) and Chisinau (Republic of Moldova).
Materials and methods. The research method was a survey of doctors of various specialties in outpatient medical organizations in Kursk – group 1 and Chisinau – group 2. From October 2019 to January 2020, 140 respondents were surveyed; the study design corresponded to a cross-sectional descriptive one.
Results. The majority of respondents gave leading positions to fluoroquinolones, cephalosporins, and drugs from other groups. For respondents of the 1st group, the priority (in descending order) were fluoroquinolones, cephalosporins, and drugs from other groups (41.0%, 24.4, and 12.2%, respectively). For doctors of the 2nd group, the leaders were drugs from other groups (26.1%), followed by fluoroquinolones and cephalosporins (25.0 and 20.5%, respectively).
Conclusion. In general, the compliance of medical prescriptions with current clinical guidelines was established. Along with this, it is necessary to note the episodic use of non-recommended groups of antibacterial drugs or their individual representatives.

Keywords

About the Authors

S.V. Povetkin, Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology, Kursk State Medical University, Kursk, Russia;
clinfarm@kursknet.ru, ORCID: https://orcid.org/0000-0002-1302-9326
A.A. Kornilov, Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology, Kursk State Medical University, Kursk, Russia; kornilovaa@kursksmu.net, eLibrary SPIN: 5736-4098, ORCID: https://orcid.org/0000-0002-0197-9826
O.V. Levashova, Cand. Sci. (Med.), Associate Professor, Associate Professor at the Department of Clinical Pharmacology, Kursk State Medical University, Kursk, Russia; levashovaov@kursksmu.net, eLibrary SPIN: 3242-2235, ORCID: https://orcid.org/0000-0002-4536-6263
Yu.A. Zhilyaeva, Cand. Sci. (Med.), Associate Professor, Department of Internal Medicine No. 2, Kursk State Medical University, Kursk, Russia; uliazhilyaeva85@yandex.ru, eLibrary SPIN: 9825-0932, ORCID: https://orcid.org/0000-0002-3844-6062 (corresponding author)
N.G. Bachinsky, Dr. Sci. (Med.), Head of Department of Pharmacology and Clinical Pharmacology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; nicolae.bacinschi@usmf.md, ORCID: https://orcid.org/0000-0003-4854-5715
L.A. Podgurski, Cand. Sci. (Med.), Associate Professor, Department of Pharmacology and Clinical Pharmacology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; ORCID: https://orcid.org/0000-0002-5922-7838
L.M. Tsurkan, Cand. Sci. (Med.), Associate Professor, Department of Pharmacology and Clinical Pharmacology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; ORCID: https://orcid.org/0000-0003-1904-9464
I.N. Golovach, Kursk State Medical University, Department of Clinical Pharmacology, Kursk, Russia; eLibrary SPIN: 4550-2186, ORCID:
https://orcid.org/0009-0004-6345-0823

Similar Articles